How many clinical trials are tracked for Anemia?

202 trials are tracked, 38 with published results.

Anemia Research — Vellito

Anemia: what the trials found

Treatment with methoxy polyethylene glycol-epoetin beta (Mircera) has demonstrated significant improvements in hemoglobin levels, including a mean increase of 2.11 from baseline at week 16 ⁸. Clinical data indicates that Mircera can maintain patients within target hemoglobin ranges; for example, approximately 53.9% of participants maintained average concentrations within the target range during the evaluation period ¹⁰, while 73.0% remained within the specific range of 10.0 to 12.0 g/dL ¹⁰. Other studies using this intervention showed high rates of maintaining hemoglobin in target ranges, reaching up to 90.9% in some cohorts ¹¹.

Epoetin alfa was evaluated for its efficacy in managing anemia; while it did not significantly differ from comparison groups regarding the percentage of patients with hemoglobin between 10 and 11 g/dL ⁶, it was also studied in relation to thrombovascular events, where no statistically significant difference was found between treatment arms ¹⁶.

Iron-based interventions show consistent utility. Iron sucrose (Venofer) demonstrated high clinical success rates, with up to 95.7% of subjects achieving success and a high percentage of patients maintaining hemoglobin levels between 10.5 g/dL and 14.0 g/dL ¹⁴. Other iron-based formulations include brand sodium ferric gluconate ³, sodium ferric gluconate complex in sucrose ¹⁸, and combined iron and zinc ¹⁵.

HIF-PH inhibitors such as Vadadustat were evaluated for cardiovascular safety; results showed no statistically significant difference in the median time to first Major Adverse Cardiovascular Event (MACE) or related hospitalizations compared to other treatments [20, 21]. Daprodustat was associated with a statistically significant difference in the time to first occurrence of adjudicated MACE or thromboembolic events ²².

For the clinician treating this condition

Methoxy polyethylene glycol-epoetin beta (Mircera) is effective for increasing hemoglobin concentrations and maintaining patients within target ranges (10.0-12.0 g/dL).
Iron sucrose (Venofer) demonstrates high clinical success rates in maintaining hemoglobin levels between 10.5 and 14.0 g/dL.
HIF-PH inhibitors like Vadadustat and Daprodustat show varying results regarding cardiovascular safety, with significant differences noted specifically for MACE or thromboembolic events in the case of Daprodustat.

AI synthesis of 10 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

1 2 3 4 Next ›

Questions about Anemia

Does taking iron powders for five months help children with malaria-induced anaemia?

Taking iron powders for five months helps children with malaria-induced anaemia by raising haemoglobin levels, but it does not improve growth measurements like height or weight.

Full answer →

Do erythropoiesis-stimulating agents help adults with heart failure and anaemia?

ESAs reduce total heart failure hospitalizations and improve hemoglobin and exercise tolerance, but do not lower first hospitalization or mortality risk.

Full answer →

How common is anemia among pregnant women who participate in the WIC program?

Anemia among pregnant WIC participants increased from 10.1% in 2008 to 11.4% in 2018, with higher rates in Black women and later trimesters.

Full answer →

Anemia

Subtypes of Anemia

Clinical Trials for Anemia

Anemia: what the trials found

For the clinician treating this condition

Questions about Anemia

All Anemia Articles